Call: +919821618106 goral@indonipponivf.com Book an Appointment
Circular teal and navy emblem logo for Indo Nippon IVF Indo Nippon IVF

IVF With PGT-A: What Australian Patients Should Know

IVF with preimplantation genetic testing for aneuploidy, commonly called PGT-A, combines assisted reproduction with chromosome screening of embryos before transfer. The approach is designed to identify embryos with the expected number of chromosomes and may help a fertility specialist select which embryo to transfer first. It is performed as part of an IVF cycle rather than as a standalone fertility test.

For patients in Australia, the decision involves medical, financial and legal considerations. PGT-A may be useful in selected circumstances, yet it cannot guarantee implantation, a healthy pregnancy or a baby. The value of testing depends on factors such as age, ovarian reserve, embryo numbers, previous treatment outcomes and the reason for seeking fertility care.

Indo Nippon IVF in Mumbai provides IVF, ICSI, embryo biopsy, genetic testing coordination and embryo transfer planning for patients from India and overseas. A specialist-led assessment can clarify whether chromosome screening is appropriate, how treatment may be organised around travel from Australia, and what follow-up care will be needed at home.

How PGT-A Works During IVF

An IVF cycle begins with ovarian stimulation, monitoring and egg collection. Eggs are fertilised in the laboratory, often through ICSI when sperm is injected directly into the egg. The resulting embryos are cultured for several days until they reach the blastocyst stage, when a small number of cells can be removed from the outer layer of the embryo.

The biopsy sample is sent to a specialist genetics laboratory for analysis. The embryo itself is usually frozen while the result is processed. PGT-A examines whether the embryo appears to have the usual number of chromosomes, a status described as euploid. An embryo with an extra or missing chromosome may be classified as aneuploid, while some results show a mixture of normal and abnormal cells and are reported as mosaic.

A euploid result can support the selection of an embryo for frozen embryo transfer, but it does not assess every possible genetic or developmental condition. PGT-A differs from PGT-M, which is used when a family has a known single-gene disorder, and PGT-SR, which investigates particular structural chromosome rearrangements. Genetic counselling helps explain which test, if any, addresses the family’s specific concern.

Who May Consider Chromosome Screening

Aneuploidy becomes more common as egg age increases, so PGT-A may be discussed with patients who are older, have experienced repeated miscarriage or have had several unsuccessful embryo transfers. It can also be considered when a previous IVF cycle produced multiple embryos and a more targeted selection process might reduce the number of transfers required.

The test is not automatically beneficial for every patient. A younger patient may produce few embryos, and biopsy or freezing could leave no embryo available for transfer. In some cases, the principal issue is low egg numbers, sperm-related infertility, uterine health or embryo development rather than chromosome selection. The treating team must consider the full clinical picture rather than treating age alone as the deciding factor.

A second opinion can be useful when recommendations differ or when a proposed testing package is difficult to understand. Patients comparing clinics may review this information about a second fertility opinion before committing to treatment. A second assessment should examine the diagnosis, expected egg yield, laboratory experience, embryo biopsy policy, genetic reporting and realistic alternatives.

The Treatment Pathway From Australia To India

Before travelling, patients generally have an online consultation, review previous blood tests and scans, and discuss sperm testing, ovarian reserve, medication and the expected duration of the visit. Some monitoring can be completed in Australia with results shared securely with the overseas clinic. The exact arrangement depends on the doctor, the Australian provider and the requirements of the laboratory.

After stimulation and egg collection in Mumbai, embryos are fertilised and grown in the clinic laboratory. Embryo biopsy and vitrification are carried out according to the treatment plan, then the PGT-A report is reviewed with the patient. Because a fresh transfer is generally not performed immediately after biopsy, many patients return to Australia while an embryo remains safely stored, then schedule a later frozen transfer.

Travel planning should include medication timing, airline arrangements, accommodation near the clinic and a plan for urgent medical contact. Sydney, Melbourne, Brisbane, Perth and other Australian cities have fertility specialists who may provide monitoring before or after overseas treatment. Patients should identify a local doctor willing to manage early pregnancy care, including blood tests and ultrasound after a positive result.

Nutrition, sleep and general health do not change an embryo’s chromosome result, but they support preparation for pregnancy and recovery from treatment. Patients who want structured dietary guidance may find nutritional support helpful alongside advice from their fertility specialist. Supplements should be checked with a doctor, particularly when taking stimulation medicines or preparing for embryo transfer.

Benefits, Limits And Possible Results

The potential benefit of PGT-A is that it may help prioritise embryos less likely to have a whole-chromosome abnormality. For some patients, this may shorten the path to a viable pregnancy by reducing transfers involving embryos unlikely to implant or likely to miscarry. It may also provide information when a patient has several blastocysts and wants a more informed transfer strategy.

There are important limits. PGT-A does not repair an embryo, improve egg quality or guarantee implantation. A tested embryo can fail to implant because of uterine factors, endometrial timing, embryo biology or causes that the test does not measure. A result classified as euploid may still have a small number of abnormal cells that were not represented in the biopsy, and a mosaic result may require specialist interpretation rather than immediate rejection.

The number of embryos available also matters. Some patients produce no blastocyst suitable for biopsy, while others receive no euploid result after testing. Laboratory fees, biopsy charges, storage and frozen transfer costs are usually separate from the core IVF fee. Patients should request an itemised estimate and ask what happens if embryos are inconclusive, mosaic or unsuitable for transfer.

PGT-A is a screening test, not a complete prenatal diagnosis. If pregnancy occurs, the obstetric team may discuss standard prenatal screening and diagnostic options such as chorionic villus sampling or amniocentesis. Results should be interpreted by qualified fertility and genetics professionals, with clear documentation passed to the Australian pregnancy-care provider.

Australian Legal And Practical Considerations

Australian fertility treatment operates within state and territory frameworks, clinic accreditation requirements and national ethical guidance. Rules and processes can vary between New South Wales, Victoria, Queensland, Western Australia, South Australia, Tasmania, the Australian Capital Territory and the Northern Territory. Patients should confirm how their home state handles consent, embryo storage, genetic testing, donor material and the use of overseas treatment.

PGT-A and embryo selection are subject to professional and regulatory requirements. Sex selection for non-medical reasons is generally restricted in Australia, while testing related to a serious sex-linked condition may be considered under specific rules. Patients should ask the Australian clinic and genetics team how results may be used and documented before authorising testing overseas.

Surrogacy requires particular caution. Commercial surrogacy is prohibited in Australia, while altruistic surrogacy is regulated differently across jurisdictions. An arrangement involving India may raise additional questions about citizenship, parentage, documentation and whether the intended parents can return home with the child. Anyone considering this route should obtain advice from Australian and Indian lawyers; background information on surrogacy options can help frame the early discussion without replacing legal advice.

Australian Medicare rebates and private health insurance benefits vary, and overseas IVF or PGT-A costs may not be covered. Patients should check their policy, obtain written confirmation from the insurer and budget for flights, accommodation, local monitoring, medicines, embryo storage, future transfers and pregnancy care. Currency changes between the Australian dollar and Indian rupee can also affect the final cost.

Practical Planning For Treatment

A careful plan reduces avoidable delays and makes the treatment pathway easier to coordinate. The first consultation should cover the medical indication for PGT-A, the expected number of eggs and blastocysts, the biopsy laboratory, the time required for results, embryo storage and the process for transferring results to the Australian care team.

Patients should also ask how embryos are graded, how mosaic or inconclusive findings are handled and whether a genetic counsellor is available. It is helpful to clarify consent forms, cancellation policies, payment schedules and the clinic’s communication process before booking flights. A written plan can prevent confusion when treatment involves several providers in different countries.

Useful preparation steps include:

An overseas treatment plan should remain flexible because ovarian response, fertilisation, embryo development and genetic results cannot be predicted precisely. Patients may need to stay longer than expected or return for a later frozen transfer. Building contingency time and funds into the travel plan is a practical part of responsible fertility care.

If you are considering chromosome testing with IVF, arrange a specialist consultation with Indo Nippon IVF to review your history, likely treatment pathway and suitability for care in Mumbai. Bring your Australian medical records and questions about laboratory methods, costs, travel, embryo transfer and follow-up so the team can develop an individualised plan.